drugset
drugset / Trial / NCT04711187

Study of AT-527 in Healthy Subjects (R07496998)

NCT04711187 ↗

Phase 1 Completed 81 enrolled Atea Pharmaceuticals, Inc. Hoffmann-La Roche · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects.

Timeline

Start
2020-11-02
Primary completion
2021-09-15
Completion
2021-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified — —

Indications

No indication recorded.